This company listing is no longer active
Provention Bio Future Growth
Future criteria checks 5/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Provention Bio.
Key information
75.7%
Earnings growth rate
64.7%
EPS growth rate
Pharmaceuticals earnings growth | 19.6% |
Revenue growth rate | 42.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 31 Mar 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 452 | 168 | 34 | 179 | 3 |
12/31/2024 | 180 | -13 | -134 | -78 | 4 |
12/31/2023 | 47 | -159 | -201 | -139 | 2 |
12/31/2022 | 13 | -114 | -76 | -75 | N/A |
9/30/2022 | 3 | -106 | -91 | -91 | N/A |
6/30/2022 | 3 | -105 | -93 | -92 | N/A |
3/31/2022 | 2 | -104 | -95 | -94 | N/A |
12/31/2021 | 1 | -114 | -96 | -95 | N/A |
9/30/2021 | 1 | -121 | -98 | -97 | N/A |
6/30/2021 | N/A | -125 | -98 | -96 | N/A |
3/31/2021 | N/A | -118 | -85 | -84 | N/A |
12/31/2020 | N/A | -99 | -77 | -76 | N/A |
9/30/2020 | N/A | -77 | -62 | -61 | N/A |
6/30/2020 | N/A | -55 | -46 | -46 | N/A |
3/31/2020 | N/A | -45 | -38 | -38 | N/A |
12/31/2019 | N/A | -43 | -36 | -36 | N/A |
9/30/2019 | N/A | -38 | -32 | -32 | N/A |
6/30/2019 | N/A | -34 | -29 | -29 | N/A |
3/31/2019 | N/A | -33 | -24 | -24 | N/A |
12/31/2018 | N/A | -27 | -23 | -23 | N/A |
9/30/2018 | N/A | -25 | -20 | -20 | N/A |
6/30/2018 | N/A | -21 | -15 | -15 | N/A |
3/31/2018 | N/A | -15 | -11 | -11 | N/A |
12/31/2017 | N/A | -9 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2VB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: 2VB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2VB is expected to become profitable in the next 3 years.
Revenue vs Market: 2VB's revenue (42.8% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 2VB's revenue (42.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2VB's Return on Equity is forecast to be high in 3 years time